• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝切除术有益于部分多发性肝细胞癌患者。

Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas.

机构信息

Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

出版信息

Ann Surg Oncol. 2022 Dec;29(13):8436-8445. doi: 10.1245/s10434-022-12495-z. Epub 2022 Sep 13.

DOI:10.1245/s10434-022-12495-z
PMID:36100832
Abstract

BACKGROUND

A single hepatocellular carcinoma (HCC) is a good indication for hepatic resection regardless of tumor size, but the surgical indications for cases with multiple HCCs remain unclear.

METHODS

We retrospectively reviewed the outcomes of hepatectomies for Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B HCCs. We further subclassified stage A and B into A1 (single nodule <5 cm, or three or fewer nodules ≤3 cm), A2 (single nodule 5-10 cm), A3 (single nodule ≥10 cm), B1 (two to three nodules >3 cm), and B2 (four or more nodules).

RESULTS

A total of 1088 patients were enrolled, comprising 88 stage 0, 750 stage A (A1: 485; A2: 190; A3: 75), and 250 stage B (B1: 166; B2: 84) cases. The 5-year overall survival (OS) rates for stage 0, A1, A2, A3, B1, and B2 patients were 70.4%, 74.2%, 63.8%, 47.7%, 47.5%, and 31.9%, respectively (p < 0.0001). Significant differences in OS were found between stages A1 and A2 (p = 0.0118), A2 and A3 (p = 0.0013), and B1 and B2 (p = 0.0050), but not between stages A3 and B1 (p = 0.4742). In stage B1 patients, multivariate analysis indicated that Child-Pugh B cirrhosis was the only independent prognostic factor for the OS outcome.

CONCLUSIONS

A hepatectomy should be considered for multiple HCCs if the number of tumors is three or fewer, especially in patients with no cirrhosis or in Child-Pugh A cases, because the long-term results are equivalent to those for a single HCC.

摘要

背景

单个肝细胞癌(HCC)是肝切除术的良好适应证,无论肿瘤大小如何,但对于多个 HCC 的手术适应证仍不清楚。

方法

我们回顾性分析了巴塞罗那临床肝癌(BCLC)分期 0、A 和 B 的 HCC 患者的肝切除术结果。我们进一步将 A 期和 B 期细分为 A1(单个结节 <5cm,或三个或更少结节 ≤3cm)、A2(单个结节 5-10cm)、A3(单个结节 ≥10cm)、B1(两个至三个结节 >3cm)和 B2(四个或更多结节)。

结果

共纳入 1088 例患者,包括 88 例 0 期、750 例 A 期(A1:485 例;A2:190 例;A3:75 例)和 250 例 B 期(B1:166 例;B2:84 例)。0 期、A1、A2、A3、B1 和 B2 患者的 5 年总生存率(OS)分别为 70.4%、74.2%、63.8%、47.7%、47.5%和 31.9%(p<0.0001)。A1 期和 A2 期(p=0.0118)、A2 期和 A3 期(p=0.0013)以及 B1 期和 B2 期(p=0.0050)之间的 OS 差异有统计学意义,但 A3 期和 B1 期之间的差异无统计学意义(p=0.4742)。在 B1 期患者中,多因素分析表明,Child-Pugh B 级肝硬化是 OS 结果的唯一独立预后因素。

结论

如果肿瘤数量为三个或更少,应考虑对多个 HCC 进行肝切除术,特别是对于没有肝硬化或 Child-Pugh A 级的患者,因为长期结果与单个 HCC 相当。

相似文献

1
Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas.肝切除术有益于部分多发性肝细胞癌患者。
Ann Surg Oncol. 2022 Dec;29(13):8436-8445. doi: 10.1245/s10434-022-12495-z. Epub 2022 Sep 13.
2
Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B.单个大肝癌(>5cm)患者的生存分析:巴塞罗那临床肝癌分期A期与B期对比
PLoS One. 2016 Nov 15;11(11):e0165722. doi: 10.1371/journal.pone.0165722. eCollection 2016.
3
Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients.肝切除术为选定的中期(BCLC-B)肝细胞癌患者带来生存获益。
Cancer Res Treat. 2019 Jan;51(1):65-72. doi: 10.4143/crt.2018.038. Epub 2018 Feb 26.
4
Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients.早期肝细胞癌的预后:基于1265例患者队列的巴塞罗那临床肝癌系统亚分期的临床意义
Medicine (Baltimore). 2015 Oct;94(43):e1929. doi: 10.1097/MD.0000000000001929.
5
Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.巴塞罗那临床肝癌分期 B 期肝癌行肝切除术的生存结局。
World J Surg Oncol. 2017 Aug 22;15(1):156. doi: 10.1186/s12957-017-1229-x.
6
Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification.巴塞罗那临床肝癌(BCLC)分期 0、A 和 B 期肝细胞癌切除后的预后:对当前 BCLC 分类的综合评估。
Ann Surg Oncol. 2019 Oct;26(11):3693-3700. doi: 10.1245/s10434-019-07580-9. Epub 2019 Jul 2.
7
Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.优化BCLC B期肝细胞癌患者的管理:现代手术切除作为经动脉化疗栓塞的可行替代方案。
Eur J Surg Oncol. 2015 Sep;41(9):1153-61. doi: 10.1016/j.ejso.2015.05.023. Epub 2015 Jun 12.
8
Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?肝细胞癌中单个大结节(>5厘米)的预后:与巴塞罗那临床肝癌(BCLC)A期或B期的关系?
Med Sci Monit. 2020 Oct 16;26:e926797. doi: 10.12659/MSM.926797.
9
Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein.肝切除术治疗“BCLC 分期 A”肝细胞癌。甲胎蛋白的预后作用。
Ann Surg Oncol. 2012 Feb;19(2):426-34. doi: 10.1245/s10434-011-1845-6. Epub 2011 Jul 6.
10
Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.基于近畿标准B2期分类的肝细胞癌患者中肿瘤因素对生存的影响
Dig Dis. 2017;35(6):583-588. doi: 10.1159/000480186. Epub 2017 Oct 17.

引用本文的文献

1
Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review.辅助性免疫检查点抑制剂能否改善肝切除术后具有高危复发因素的肝细胞癌的长期预后?一项荟萃分析和系统评价。
Front Oncol. 2024 May 24;14:1374262. doi: 10.3389/fonc.2024.1374262. eCollection 2024.
2
Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy.术前循环肿瘤细胞对肝癌患者肝切除术后早期进展复发的预测预后潜力。
BMC Cancer. 2023 Nov 27;23(1):1150. doi: 10.1186/s12885-023-11629-0.
3

本文引用的文献

1
Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.中国肝癌新辅助和转化治疗专家共识。
World J Gastroenterol. 2021 Dec 21;27(47):8069-8080. doi: 10.3748/wjg.v27.i47.8069.
2
Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy.分子治疗后肝细胞癌的转化手术。
Anticancer Res. 2022 Jan;42(1):35-44. doi: 10.21873/anticanres.15454.
3
Conversion surgery for hepatocellular carcinoma after multidisciplinary treatment including lenvatinib.包括乐伐替尼在内的多学科治疗后肝细胞癌的转化手术
A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study.
决策树模型预测肝细胞癌患者的肝硬化:一项回顾性研究。
PeerJ. 2023 Aug 24;11:e15950. doi: 10.7717/peerj.15950. eCollection 2023.
4
Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.术后辅助酪氨酸激酶抑制剂联合抗 PD-1 抗体可改善具有高危复发因素的肝细胞癌的手术效果。
Front Immunol. 2023 Jun 8;14:1202039. doi: 10.3389/fimmu.2023.1202039. eCollection 2023.
Hepatol Res. 2021 Oct;51(10):1029-1030. doi: 10.1111/hepr.13691.
4
Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.仑伐替尼治疗晚期肝细胞癌后手术干预的预后影响。
Ann Surg Oncol. 2021 Nov;28(12):7663-7672. doi: 10.1245/s10434-021-09974-0. Epub 2021 Apr 26.
5
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.肝细胞癌的试验设计与终点:美国肝病研究学会共识会议
Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9.
6
Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion.BCLC 中期无微血管侵犯肝细胞癌患者行肝切除术是合理的。
J Gastrointest Surg. 2020 Dec;24(12):2737-2747. doi: 10.1007/s11605-019-04251-8. Epub 2019 Nov 25.
7
Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis.建立预测 Child-Pugh B 级肝硬化肝癌患者肝切除术后结局的列线图。
J Hepatol. 2020 Jan;72(1):75-84. doi: 10.1016/j.jhep.2019.08.032. Epub 2019 Sep 6.
8
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.肝细胞癌临床实践指南:日本肝脏学会2017年(第4版日本肝脏学会肝细胞癌指南)2019年更新版
Hepatol Res. 2019 Oct;49(10):1109-1113. doi: 10.1111/hepr.13411. Epub 2019 Sep 6.
9
Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification.巴塞罗那临床肝癌(BCLC)分期 0、A 和 B 期肝细胞癌切除后的预后:对当前 BCLC 分类的综合评估。
Ann Surg Oncol. 2019 Oct;26(11):3693-3700. doi: 10.1245/s10434-019-07580-9. Epub 2019 Jul 2.
10
Hepatocellular Carcinoma.肝细胞癌
N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263.